Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro®)

Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro®) AbstractProphylactic coagulation factor replacement is increasingly the treatment modality of choice for people with haemophilia (PWH). Currently available recombinant factor products require reconstitution from a lyophilised powder and diluent, and a range of infusion systems is available to assist in this process. This study aimed to understand the properties of a reconstitution/infusion system that are most important to PWH and carers of children with haemophilia (CWH), and to assess two available systems produced by Novo Nordisk for the reconstitution and infusion of activated recombinant factor VII and recombinant factor VIII: the original infusion system and the newer MixPro® system. Both were tested by a group of 67 PWH or carers of CWH who were naïve to them. Participants rated the performance of each system against 18 predefined parameters using the 7-point Likert scale, and ranked the importance of these parameters to the design of an infusion system. They also directly compared the performance of the two systems and provided qualitative feedback. Overall, MixPro® was preferred to the original system by 94% of study participants. This was reflected in the performance scores for individual parameters, with scores in 16/18 parameters being significantly higher for MixPro® (p<0.05) than the original system. Low contamination risk was seen as the most important criterion in the design and choice of an infusion system, with 97% regarding MixPro® as the superior system in this category. The MixPro® system was perceived as being quick, easy to use, convenient and portable. It is hoped that these findings may help guide the future design of infusion systems for PWH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Haemophilia Practice de Gruyter

Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro®)

Download PDF
6 pages

Loading next page...
 
/lp/de-gruyter/patient-and-caregiver-perceptions-of-a-pre-filled-diluent-syringe-SNcu8PrJVb
Publisher
de Gruyter
Copyright
© 2016 Jim Munn, Kate Khair, Andrew Scott, Robyn Shoemark, Julia Spires, Morten Lind Jensen, Reto Wirz, published by Sciendo
eISSN
2055-3390
DOI
10.17225/jhp00073
Publisher site
See Article on Publisher Site

Abstract

AbstractProphylactic coagulation factor replacement is increasingly the treatment modality of choice for people with haemophilia (PWH). Currently available recombinant factor products require reconstitution from a lyophilised powder and diluent, and a range of infusion systems is available to assist in this process. This study aimed to understand the properties of a reconstitution/infusion system that are most important to PWH and carers of children with haemophilia (CWH), and to assess two available systems produced by Novo Nordisk for the reconstitution and infusion of activated recombinant factor VII and recombinant factor VIII: the original infusion system and the newer MixPro® system. Both were tested by a group of 67 PWH or carers of CWH who were naïve to them. Participants rated the performance of each system against 18 predefined parameters using the 7-point Likert scale, and ranked the importance of these parameters to the design of an infusion system. They also directly compared the performance of the two systems and provided qualitative feedback. Overall, MixPro® was preferred to the original system by 94% of study participants. This was reflected in the performance scores for individual parameters, with scores in 16/18 parameters being significantly higher for MixPro® (p<0.05) than the original system. Low contamination risk was seen as the most important criterion in the design and choice of an infusion system, with 97% regarding MixPro® as the superior system in this category. The MixPro® system was perceived as being quick, easy to use, convenient and portable. It is hoped that these findings may help guide the future design of infusion systems for PWH.

Journal

The Journal of Haemophilia Practice – de Gruyter

Published: Jan 1, 2016

References

  • Children’s preferences of transfer devices for reconstitution of factors VIII and IX for the treatment of haemophilia
  • Learning intravenous infusion in haemophilia: experience from the Netherlands
  • Learning intravenous infusion in haemophilia: experience from the Netherlands
  • Changing pattern of care of boys with haemophilia in western European centres
  • Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
  • A survey of adherence to haemophilia therapy in six European countries: results and recommendations
  • Evaluating a self infusion device for children with haemophilia
  • Children’s preferences of transfer devices for reconstitution of factors VIII and IX for the treatment of haemophilia
  • Postmarketing surveillance study of Kogenate Bayer with Bio-Set in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system
  • Prophylactic therapy in haemophilia
  • Guidelines for the management of hemophilia
  • Changing pattern of care of boys with haemophilia in western European centres
  • Barriers and perceived limitations to early treatment of hemophilia
  • A survey of adherence to haemophilia therapy in six European countries: results and recommendations
  • Patient preference for needleless factor VIII reconstitution device: the Italian experience
  • Prophylactic therapy in haemophilia
  • Guidelines for the management of hemophilia
  • Postmarketing surveillance study of Kogenate Bayer with Bio-Set in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system
  • Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
  • Evaluating a self infusion device for children with haemophilia
  • Patient preference for needleless factor VIII reconstitution device: the Italian experience
  • Barriers to compliance with prophylaxis therapy in haemophilia
  • Barriers and perceived limitations to early treatment of hemophilia
  • Barriers to compliance with prophylaxis therapy in haemophilia